Janux Therapeutics (NASDAQ:JANX) Given New $15.00 Price Target at Barclays

Janux Therapeutics (NASDAQ:JANX) had its target price hoisted by Barclays from $14.00 to $15.00 in a research note issued to investors on Friday morning,Benzinga reports. Barclays currently has an underweight rating on the stock.

Several other analysts have also weighed in on the stock. Stifel Nicolaus set a $35.00 price objective on shares of Janux Therapeutics in a report on Friday, August 7th. HC Wainwright reiterated a “buy” rating on shares of Janux Therapeutics in a research report on Monday, October 19th. Guggenheim cut their price target on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Friday, October 16th. Finally, Wolfe Research raised shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price objective for the company in a research report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Janux Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $36.92.

Janux Therapeutics Stock Performance

Shares of JANX traded up $1.57 during trading hours on Friday, reaching $17.63. 852,234 shares of the company traded hands, compared to its average volume of 769,690. The stock’s fifty day moving average is $17.49 and its 200 day moving average is $15.42. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The stock has a market cap of $1.08 billion, a P/E ratio of -11.09 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13. The firm had revenue of $9.29 million during the quarter, compared to analyst estimates of $8.03 million. On average, equities research analysts predict that Janux Therapeutics will post -1.70 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Diversified Trust Co grew its stake in shares of Janux Therapeutics by 3.5% during the third quarter. Diversified Trust Co now owns 17,429 shares of the company’s stock worth $301,000 after buying an additional 588 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Janux Therapeutics by 67.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after acquiring an additional 661 shares in the last quarter. Versant Capital Management Inc grew its position in Janux Therapeutics by 42.8% during the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after acquiring an additional 784 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in Janux Therapeutics by 8.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 12,350 shares of the company’s stock worth $213,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Quantinno Capital Management LP increased its holdings in Janux Therapeutics by 7.6% in the 1st quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock worth $362,000 after purchasing an additional 1,846 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics News Roundup

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
• Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
• Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
• Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
• Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.